[{"orgOrder":0,"company":"Xinvento","sponsor":"Rhythm Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Xinvento","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xinvento \/ Rhythm Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Xinvento \/ Rhythm Pharmaceuticals"},{"orgOrder":0,"company":"VectorY","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"VectorY \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"VectorY \/ Inapplicable"},{"orgOrder":0,"company":"VectorY","sponsor":"Wageningen University","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"VectorY \/ Wageningen University","highestDevelopmentStatusID":"4","companyTruncated":"VectorY \/ Wageningen University"},{"orgOrder":0,"company":"Vico Therapeutics","sponsor":"Life Science Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vico Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vico Therapeutics \/ Life Science Partners","highestDevelopmentStatusID":"4","companyTruncated":"Vico Therapeutics \/ Life Science Partners"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : Imcivree (setmelanotide) is a melanocortin 4 (MC4) receptor agonist indicated for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity

                          Product Name : Imcivree

                          Product Type : Peptide

                          Upfront Cash : $5.0 million

                          February 27, 2023

                          Lead Product(s) : Setmelanotide Acetate

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : Rhythm Pharmaceuticals

                          Deal Size : $211.0 million

                          Deal Type : Acquisition

                          blank

                          02

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : VecTabs, which are secreted- or intracellular-antibody fragments that are AAV-vectorized and delivered to neurons and/or astrocytes, have previously been shown to efficiently target such misfolded proteins (TDP-43) and toxic lipids (oxPL).

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          August 23, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : VICO’s lead antisense oligonucleotide product, VO659 is designed to suppress mutant proteins and slow or halt disease progression.

                          Product Name : VO659

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          July 29, 2021

                          Lead Product(s) : VO659

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : Vico will use this funding to further advance its late preclinical stage Antisense OligoNucleotides lead platform for the development of therapies for different forms of Spinocerebellar Ataxia (SCA) and Huntington Disease (HD) into first-in-human clinica...

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Undisclosed

                          July 30, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : Life Science Partners

                          Deal Size : $31.0 million

                          Deal Type : Series A Financing

                          blank